The government’s top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval ...

Pfizer (PFE) closed at $25.32 in the latest trading session, marking a +1.12% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.48% for the day. Elsewhere, the Dow ...

Shares of Pfizer Inc. PFE rose 1.12% to $25.32 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.47% to 6,227.42 and the Dow ...

Pfizer exec Philip Dormitzer amid claims the COVID-19 vaccine announcement was delayed to avoid influencing the 2020 election ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

We view Pfizer’s dividends and share repurchase levels as reasonable. Pfizer has generally targeted close to a 50% payout in dividends as a percentage of normalized earnings, which seems about right ...

The House Judiciary Committee subpoenaed a former Pfizer executive who allegedly claimed senior members of the company ...

A former Pfizer scientist was subpoenaed Monday by House Republicans over allegations that there was a conspiracy among ...

While Pfizer's revenue and earnings did experience a sharp decline following the normalization of COVID-19 product demand, the company's 2025 guidance suggests stabilization is at hand.

Pfizer's dividend payout ratio of 122.5% looks concerning at first glance. A company can only pay out more in dividends than it generates in earnings for a limited time.

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years. Shares are down 19% over ...

Key Points Pfizer offers a substantial 6.7% dividend yield and has increased its dividend for 16 consecutive years. The stock trades at a forward P/E of just 8.7, close to historical lows.